Background {#Sec1}
==========

Drug-resistant tuberculosis (TB) is a public health concern threathing the success of TB control efforts. This is particularily problematic in the Central Asian Republics (CARs) Uzbekistan, Tajikistan, and Kyrgyzstan where multidrug-resistant (MDR)-TB rates reach 24%, 22%, 27%, and 63%, 45% and 60% among new and previously treated cases, respectively \[[@CR1]\].

Little is known about the population structure of drug resistant *Myocbacterium tuberculosis* (MTB) strains in Central Asia. Available reports are limited by either outdated genotyping techniques, sampling of special populations and/or small sample sizes \[[@CR2]--[@CR4]\]. Here, we provide a snapshot of the population structure of MTB strains based on World Health Organization resistance surveys performed in Kyrgyzstan, Tajikistan, and Uzbekistan representing two thirds of the Central Asian population.

For genotyping we combined 24-loci MIRU-VNTR typing (Mycobacterial Interspersed Repetitive Units - Variable Number of Tandem Repeats) with spoligotyping. MIRU-VNTR provides high-resolution discrimination of strains for epidemiological studies and phylogenetic classification \[[@CR5]\]. MIRU-VNTR data allow also to generate parsimonious phylogenetic networks such as minimum-spanning trees (MST) \[[@CR6]\]. These results were combined with phenotypic drug susceptibility data to determine the presence of highly resistant dominant clones.

Methods {#Sec2}
=======

Seven hundred and seven clinical MTB isolates (306 from Uzbekistan, 216 from Tajikistan, and 185 from Kyrgyzstan) were collected in the framework of cross-sectional national drug resistance surveys (DRS) \[[@CR7], [@CR8]\] and included in the study. The study population was biased towards resistant strains since only isolates that required re-testing for quality control purposes as per the WHO DRS protocol which was valid at the time were included \[[@CR8]\]. This approach artificially increased the proportion of MDR-,pre-extensively drug-resistant (pre-XDR) and XDR-TB strains. Ethical approvals for the DRSs were granted by the respective national ethical committees.

DNA was extracted by heat lysis of bacteria from solid culture on LJ medium. 24-loci MIRU-VNTR genotyping and spoligotyping was performed as previously described \[[@CR5], [@CR9]\]. Genotypes were identified on the MIRU-VNTR*plus* web database ([www.miruvntrplus.org](http://www.miruvntrplus.org)) \[[@CR5]\]. Spoligotyping data were used to confirm strain relationships and for genotype classification. Typing data was analysed with Bionumerics (v7.5; Applied Maths, Sint-Martens-Latem, Belgium). MST analysis based on MIRU-VNTR data was performed using the categorical coefficient. For each 24-loci MIRU-VNTR pattern a unique multiple loci VNTR analysis (MLVA) MtbC15--9 haplotype was assigned by using the MIRU-VNTR*plus* nomenclature \[[@CR10]\]. A cluster was defined as a minimum of two isolates harboring identical genotyping patterns from different patients. Patients with mixed molecular typing patterns were excluded. Drug susceptibility testing was performed by the resazurin microtiter assay \[[@CR11]\].

Results {#Sec3}
=======

Twenty four-loci MIRU-VNTR typing and spoligotyping were successfully performed for 607 isolates, while 76 isolates (62 from Uzbekistan, seven from Tajikistan, and seven from Kyrgyzstan) yielded indeterminate results. For 23 isolates (9 from Uzbekistan, three from Tajikistan, and 11 from Kyrgyzstan), mixed genotyping patterns were observed. One isolate from Kyrgyzstan had incomplete phenotypic data.

The final study set consisted of 607 isolates of which 235 (38.7%) originated from Uzbekistan, 206 (33.9%) from Tajikistan, and 166 (27.3%) from Kyrgyzstan (Table [1](#Tab1){ref-type="table"}). The male to female ratio of patients was 1.5 and ages ranged from 12 to 85 years with a mean of 37.9 years (SD ±15.7). Across the three countries, 333 (54.9%) were new and 221 (36.4%) previously treated cases (for 53 patients information regarding previous treatments was missing; Table [1](#Tab1){ref-type="table"}). Thirty five isolates (5.8%) were pan-susceptible, 293 (48.3%) MDR-, pre-XDR, or XDR-TB, while the remaining 279 isolates (46.0%) had any other resistance pattern. MDR- and XDR-TB were more prominent among Kyrgyz (33%) and Tajik (35%) than among Uzbek isolates (20%), which was mainly attributable to different re-testing algorithms in the DRS protocols. Table 1Demographic data, genotypes, haplotypes and phenotypes of the Central Asian *M. tuberculosis* complex study populationAll countriesUzbekistanTajikistanKyrgystanNo. strains%SDNo. strains%SDNo. strains%SDNo. strains%SD*Samples*60723538.720633.916627.3*Gender* Male35959.113959.112058.310060.2 Female23939.49640.98541.35834.9 Unknown9018*Age* ^*a*^ Mean37.9415.6742.9116.634.5314.3634.1813.49*Treatment* New33354.915666.49345.18450.6 Previous22136.47933.611354.92917.5 Unknown530053*MIRU lineage* Beijing41167.713657.915474.812172.9 Dehli/CAS6162.6 H37Rv-like609.93113.2125.81710.2 LAM365.9229.452.495.4 NEW-1315.1166.8104.953 URAL284.6104.3115.374.2 Haarlem264.373136.363.6 S-type30.520.910.6 TUR10.210.5 X-type10.210.4 Undefined40.741.7*MLVA MtbC15--9* 94--32 (Beijing)14523.95824.74923.83822.9 100--32 (Beijing)7011.5125.15124.874.2*Resistance pattern* Pan-susceptible355.8218.921127.2 Other resistances279461275466328651.8 MDR-TB17228.347207134.55432.5 Pre XDR-TB9415.53414.55024.3106 XDR-TB274.462.6178.342.4^a^Unkown for Tajikistan and 23 unkown for Kyrgystan*SD* standard deviation

Based on the MIRU-VNTR profiles and spoligotyping patterns, 603 isolates were classified into previously described lineages (Table [1](#Tab1){ref-type="table"}). 411 (67.7%) isolates belonging to lineage 2 (East-Asian; Beijing genotype) \[[@CR12]\]. Six (1.0%) isolates belonged to lineage 3 (East-African-Indian; Delhi/CAS genotype), and 186 (30.6%) isolates belonged to lineage 4 (Euro-American) with the predominiating genotypes H37Rv-like (60; 9.9%), LAM (36; 5.9%), NEW-1 (31; 5.1%), URAL (28; 4.6%), and Haarlem (26; 4.3%). Four (0.7%) isolates could not be linked to a previously described lineage and were classified as "undefined". An MST was calculated (Fig. [1](#Fig1){ref-type="fig"}) confirming the UPGMA (unweighted pair group method with arithmetic mean) tree-based genotype classification of MIRU-VNTR*plus* (data not shown). Fig. 1Minimum spanning tree based on the 24-loci MIRU-VNTR typing data of 607 MTB isolates from Uzbekistan, Tajikistan and Kyrgyzstan. The size of each circle is proportional to the number of MIRU-VNTR types belonging to a particular complex. Classification of the isolates into the different phylogenetic lineages and resistance patterns is visualized by color coding

Cluster analysis revealed that 382 (62.9%) of the 607 isolates shared a genotyping pattern with at least one other isolate. They were grouped in 38 clusters ranging from two to 145 isolates. The two largest clusters had haplotypes 94--32 (*n* = 145; 23.9%) and 100--32 (*n* = 70; 11.5%) (Fig. [1](#Fig1){ref-type="fig"}). The prevalence of 94--32 was equally distributed over the CARs whereas cluster 100--32 was particularly prominent in Tajikistan (51 strains; 72.9%). 349 (84.9%) of the 411 Beijing isolates formed clusters, compared to only 33 (16.8%) of the 196 isolates from other clades.

Beijing strains were more frequently MDR-, pre-XDR- or XDR-TB (265/411; 64.5%) than strains of other genotypes (28/196; 14.3%; no XDR-TB) (Fig. [2](#Fig2){ref-type="fig"}). Beijing cluster 94--32 showed the same drug resistance pattern as other Beijing strains, whereas cluster 100--32 was almost completely (66/70; 94.3%) MDR, pre-XDR, or XDR. Fig. 2Proportions of isolates based on drug resistance patterns. The number of isolates with a given genotype/MLVA MtbC15--9 haplotype is given above the corresponding column

Discussion {#Sec4}
==========

High prevalence of Beijing strains has previously been reported from Central Asia \[[@CR4]\]. The star-like shape of the lineage 2/Beijing population in Fig. [1](#Fig1){ref-type="fig"} with two central clones surrounded by layers of single and multi-locus variants is a typical pattern for emerging and expanding MTB populations \[[@CR13]\]. The two largest clusters 94--32 and 100--32 were found in all three Central Asian countries and represented more than a third of all study isolates indicating strong population expansion across borders. Our findings confirm the results of a global Beijing population study which reported that 94--32 and 100--32 were predominantly prominent in Uzbekistan, Russia and Eastern European countries and had particularly high clustering rates \[[@CR13]\]. The smaller size of 100--32 and its unequal distribution to the three CARs suggest however its more recent arrival in Central Asia and a shorter regional expansion time than of 94--32. This hypothesis is further supported by Mokrousov \[[@CR14]\] and Skibe et al. \[[@CR15]\] who have already reported 100--32 as minor group (\< 4%) of Beijing isolates in Central Asia while it reached proportions of over 10% and over 20% in Eastern Europe and Russia, respectively, and while Skibe et al. observed 94--32 as dominant cluster in Kazakhstan. The extent of cross-border spread and locally restricted transmisison networks can however not be ultimately resolved with MIRU-VNTR cluster data and require further investigation with higher resolution.

High percentages of MDR among Beijing strains has also been reported from other Eastern European countries, like Georgia, Kazakhstan, and Uzbekistan \[[@CR4], [@CR15], [@CR16]\]. Higher proportions of MDR- and XDR-TB were also observed within the 100--32 genotype by Merker and colleagues \[[@CR13]\]. The authors analyzed the full genomes of MDR-TB strains belonging to MLVA-VNTR haplotypes 94--32 and 100--32 and showed that the maximal divergences were 17 and 23 SNPs, respectively, within genomes of those clusters \[[@CR13]\].

Our data indicate that spread of resistant MTB strains, particularly of lineage 2/Beijing, is an important root of the ongoing MDR-TB epidemic in Central Asia. MIRU-VNTR is a powerful tool for investigating population structures and transmission dynamics, however, advances in the field of whole genome sequencing have resulted in molecular methods that can give better resolution and should ideally be used to elucidate specific transmission pathways. Analyzing the full genomes of this or an unbiased and thus even more representative study population could provide an even deeper insight into the MTB population structure in CAR.

Conclusions {#Sec5}
===========

Clusters 94--32 and 100--32 are the dominant genotypes driving population expansion of Beijing strains in the CARs Uzbekistan, Tajikistan, and Kyrgyzstan. The data demonstrate that spread of resistant TB strains, particularly of the Beijing lineage and its clusters 94--32 and 100--32, is an important root of the ongoing MDR-TB epidemic in Central Asia. Measures to combat this epidemic need to be improved.
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